# OnCo record paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014" ;
  schema:name "EORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma"@en ;
  schema:description "Adding ifosfamide to doxorubicin for advanced soft tissue sarcoma doubled the response rate and delayed progression but did not lengthen survival and caused much more toxicity, so doxorubicin alone remains the default unless shrinkage is needed."@en ;
  schema:url <https://onco.cc/key-papers/paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(14)70063-4>, <https://pubmed.ncbi.nlm.nih.gov/24618336/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(14)70063-4> ;
  schema:datePublished "2014"^^xsd:gYear ;
  schema:author "Judson I, Verweij J, Gelderblom H, et al." ;
  onco:cancers <https://onco.cc/cancers/malignant-peripheral-nerve-sheath-tumour/>, <https://onco.cc/cancers/extremity-soft-tissue-sarcoma/>, <https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/>, <https://onco.cc/cancers/leiomyosarcoma/>, <https://onco.cc/cancers/myxofibrosarcoma/>, <https://onco.cc/cancers/synovial-sarcoma/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/ifosfamide/> ;
  onco:trials <https://onco.cc/trials/eortc-62012/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .